CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USAWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug678 Clevudine Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.27
D001778 Blood Coagulation Disorders NIH 0.27

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.27

There is one clinical trial.

Clinical Trials


1 Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

NCT04479280 Coagulation Disorder Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
MeSH:Hemostatic Disorders Blood Coagulation Disorders
HPO:Abnormality of coagulation Abnormality of the coagulation cascade

Primary Outcomes

Description: measuring how rapid the sample will get clotted

Measure: clot rate formation

Time: 30 minutes


Related HPO nodes (Using clinical trials)